The recent aesthetic sector licencing amendment contained within the Health and Care Act (2022) and the enactment of the Botulinum Toxins and Cosmetic Fillers (Children) Act (2021) have caused prescribing in cosmetic procedures to come under close scrutiny. Discussions in both Houses of the Lords and Commons have been openly critical with regard to standards of prescribing for cosmetic procedures, presenting clear implications for professional and industry credibility and for patient safety.
To read our press release click here
Your session timed-out.
Please Re-Login to Continue.
You have chosen invalid value.
We cannot continue with your application at this time.
Currently you do not meet the criteria to join the JCCP register and we cannot continue with your application at this time.